Glenmark Pharmaceuticals just launched its Travoprost Ophthalmic Solution USP 0.004% (ionic buffered solution) in the US market. Glenmark Pharmaceuticals' says its product, a prostaglandin analog, is bioequivalent and therapeutically equivalent to Sandoz's Travatan Z, which is approved for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma. 

A company press release quoted IQVIA sales data for the 12-month period ending September 2024 showing the Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million. Glenmark’s current portfolio consists of 200 products authorized for distribution in the US marketplace and 51 abbreviated new drug applications pending approval with the FDA.